Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Macrophage ferritin heavy chain/α-synuclein regulatory axis modulates ferroptosis during kidney injury
Tanima Chatterjee, Sarah Machado, Kellen Cowen, Mary E. Miller, Bronte Johnson, Yanfeng Zhang, Laura A. Volpicelli-Daley, Lauren A. Fielding, Rudradip Pattanayak, Frida Rosenblum, László Potor, György Balla, Jozsef Balla, Christian Faul, Abolfazl Zarjou
Tanima Chatterjee, Sarah Machado, Kellen Cowen, Mary E. Miller, Bronte Johnson, Yanfeng Zhang, Laura A. Volpicelli-Daley, Lauren A. Fielding, Rudradip Pattanayak, Frida Rosenblum, László Potor, György Balla, Jozsef Balla, Christian Faul, Abolfazl Zarjou
View: Text | PDF
Research Article Immunology Nephrology

Macrophage ferritin heavy chain/α-synuclein regulatory axis modulates ferroptosis during kidney injury

  • Text
  • PDF
Abstract

Macrophages, endowed with remarkable phenotypic plasticity, are essential for orchestrating injury responses and regulating iron homeostasis. Given the central role of ferritin heavy chain (FtH) as a molecular rheostat linking iron sequestration to redox-dependent signaling, we examined how myeloid FtH governs renal iron trafficking and ensuing oxidative stress pathways during acute kidney injury (AKI). Transcriptome analysis revealed coupling of FtH deficiency in monocytes and macrophages with activation of ferroptosis, a regulated cell death associated with iron accumulation. Moreover, myeloid FtH deletion worsened AKI, increasing leukocyte infiltration and iron deposition, together with ferroptosis-associated gene induction, oxidative stress, and lipid peroxidation. Notably, α-synuclein (SNCA), an iron-binding protein and the main pathological driver of Parkinson’s disease, was robustly induced both by FtH deficiency and following AKI. Mechanistic studies showed that monomeric SNCA exhibits ferrireductase activity, amplifying redox cycling and promoting ferroptotic cell death. Furthermore, SNCA expression was elevated in kidney pathologies characterized by leukocyte expansion in both mouse models and human cohorts, suggesting that inflammatory microenvironments promote SNCA accumulation and redox imbalance. These findings define a macrophage FtH/SNCA regulatory axis as a key driver of ferroptosis in AKI, implicating SNCA as a pathological nexus between iron dyshomeostasis and inflammatory kidney injury.

Authors

Tanima Chatterjee, Sarah Machado, Kellen Cowen, Mary E. Miller, Bronte Johnson, Yanfeng Zhang, Laura A. Volpicelli-Daley, Lauren A. Fielding, Rudradip Pattanayak, Frida Rosenblum, László Potor, György Balla, Jozsef Balla, Christian Faul, Abolfazl Zarjou

×

Figure 7

SNCA accumulation is a hallmark of kidney diseases marked by leukocyte expansion across species.

Options: View larger image (or click on image) Download as PowerPoint
SNCA accumulation is a hallmark of kidney diseases marked by leukocyte e...
(A–D) Western blot analysis of monomeric SNCA in kidney lysates from 4 different mouse models of kidney disease: (A) WT mice were treated with vehicle or AA. Kidney lysates were collected 6 weeks after AA administration. (B) WT mice were subjected to 20 minutes of ischemia/reperfusion (I/R) injury. Kidney samples were collected at indicated time points. (C) Protein expression of SNCA in WT kidneys treated with cisplatin as described in Methods. (D) SNCA expression in kidneys from WT (Col4a3+/+) and Alport (Col4a3–/–) mice at 12 weeks of age. (E–H) Densitometric analysis of SNCA protein expression in nephropathy models: AA (vehicle, n = 5; AA, n = 8) (E), I/R (sham, n = 5; days 1, 7, 28, n = 5 per time point) (F), cisplatin (vehicle, n = 4; cisplatin, n = 5) (G), and Alport syndrome (n = 5 per genotype) (H), normalized to GAPDH. (I) Serum creatinine levels in vehicle- and cisplatin-treated mice (vehicle, n = 6; cisplatin, n = 9). (J) Serum creatinine in WT and Alport mice measured at 12 weeks of age (n = 5 per genotype). (K and L) Analysis of Snca expression using publicly available scRNA-seq datasets from healthy (K) and rejected (ACR) (L) human kidney allografts. Arrows indicate monocyte/macrophage expression of Snca in healthy (K) and ACR (L) kidneys. (M) H&E stain (left) highlights histopathological features of human kidney biopsies from patients with TBM disease, acute interstitial nephritis (AIN), and acute cellular allograft rejection (ACR). Immunofluorescence staining of SNCA and CD11b validates overlap in AIN and ACR, but not in TBM. Scale bars: H&E stains, 100 μm; immunofluorescence, 25 μm. (N) Higher-magnification overlay images of a healthy-appearing glomerulus in TBM and a case of glomerulitis in ACR. Scale bars: 25 μm. NS, not significant; *P < 0.05, **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts